Egetis Therapeutics (Sweden) Probability of Future Stock Price Finishing Over 9.61
| EGTX Stock | SEK 5.61 0.21 3.89% |
Egetis |
Egetis Therapeutics Target Price Odds to finish over 9.61
The tendency of Egetis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over kr 9.61 or more in 90 days |
| 5.61 | 90 days | 9.61 | near 1 |
Based on a normal probability distribution, the odds of Egetis Therapeutics to move over kr 9.61 or more in 90 days from now is near 1 (This Egetis Therapeutics AB probability density function shows the probability of Egetis Stock to fall within a particular range of prices over 90 days) . Probability of Egetis Therapeutics price to stay between its current price of kr 5.61 and kr 9.61 at the end of the 90-day period is about 8.19 .
Assuming the 90 days trading horizon Egetis Therapeutics has a beta of 0.93 suggesting Egetis Therapeutics AB market returns are related to returns on the market. As the market goes up or down, Egetis Therapeutics is expected to follow. Additionally Egetis Therapeutics AB has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Egetis Therapeutics Price Density |
| Price |
Predictive Modules for Egetis Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Egetis Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Egetis Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Egetis Therapeutics is not an exception. The market had few large corrections towards the Egetis Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Egetis Therapeutics AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Egetis Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.09 | |
β | Beta against Dow Jones | 0.93 | |
σ | Overall volatility | 0.51 | |
Ir | Information ratio | -0.02 |
Egetis Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Egetis Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Egetis Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Egetis Therapeutics had very high historical volatility over the last 90 days | |
| Egetis Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 38.24 M. Net Loss for the year was (104.54 M) with loss before overhead, payroll, taxes, and interest of (58.28 M). | |
| Egetis Therapeutics AB has accumulated about 207.41 M in cash with (130.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.26. | |
| Roughly 52.0% of the company shares are held by company insiders |
Egetis Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Egetis Stock often depends not only on the future outlook of the current and potential Egetis Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Egetis Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 107.5 M | |
| Cash And Short Term Investments | 144 M |
Egetis Therapeutics Technical Analysis
Egetis Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Egetis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Egetis Therapeutics AB. In general, you should focus on analyzing Egetis Stock price patterns and their correlations with different microeconomic environments and drivers.
Egetis Therapeutics Predictive Forecast Models
Egetis Therapeutics' time-series forecasting models is one of many Egetis Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Egetis Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Egetis Therapeutics
Checking the ongoing alerts about Egetis Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Egetis Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Egetis Therapeutics had very high historical volatility over the last 90 days | |
| Egetis Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 38.24 M. Net Loss for the year was (104.54 M) with loss before overhead, payroll, taxes, and interest of (58.28 M). | |
| Egetis Therapeutics AB has accumulated about 207.41 M in cash with (130.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.26. | |
| Roughly 52.0% of the company shares are held by company insiders |
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.